1)Simonneau G, et al:Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 53:1801913, 2019
2)Ghigna MR, et al:BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension. Eur Respir J 48:1668-1681, 2016
3)Nossent EJ, et al:Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2(GCN2)in pulmonary veno-occlusive disease. J Heart Lung Transplant 37:647-655, 2018
4)Overbeek MJ, et al:Pulmonary arterial hypertension in limited cutaneous systemic sclerosis;A distinctive vasculopathy. Eur Respir J 34:371-379, 2009
5)Galiè N, et al:Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 373:834-844, 2015
6)Galiè N, et al:Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 53:1801889, 2019
7)Kato M, Atsumi T:Pulmonary arterial hypertension associated with connective tissue diseases;A review focusing on distinctive clinical aspects. Eur J Clin Invest 48:e12876, 2018
8)Vachiery JL, et al:Pulmonary hypertension due to left heart disease. Eur Respir J 53:1801897, 2019
9)Fayyaz AU, et al:Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction. Circulation 137:1796-1810, 2018
10)Nathan SD, et al:Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 53:1801914, 2019
11)Kato M, et al:Diagnostic and prognostic markers and treatment of connective tissue disease-associated pulmonary arterial hypertension;Current recommendations and recent advances. Exp Rev Clin Immunol, 2020(in press)
12)Coghlan JG, et al:Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis;The DETECT study. Ann Rheum Dis 73:1340-1349, 2014
13)Shirai Y, et al:Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension;A single-centre cohort. Rheumatology(Oxford)51:1846-1854, 2012